Ceftriaxone in amyotrophic lateral sclerosis

One hundred and eight patients with amyotrophic lateral sclerosis (ALS) received ceftriaxone 2 g daily i.v. (62) or i.m. (34) or by both routes (12), for 21-day cycles on an open basis, Baseline MRC and Norris scores were similar to those at the end of the first 21-day cycle of therapy, Seven patients showed remarkable clinical improvement, mostly segmental, which started during the first week of treatment and lasted up to 2 months after its completion, Improvement was also noted in seven out of 21 cases given a subsequent cycle of treatment. Based on these findings, the drug is supposed to act by altering the neurochemical transmission at the neuromuscular junction and/or by facilitating the presynaptic uptake of glutamate at the synaptic junction, This hypothesis positively correlates with the results of in vitro experiments showing that ceftriaxone increases H-3-glutamate uptake in rat spinal cord synaptosomes.